那吶妥單抗

化合物

那吶妥單抗INN:Narnatumab;開發代號:IMC-RON8LY3012219[1]是一種針對RON英語MST1R受體的人單株抗體,設計用於治療直腸癌和由淋巴管生成英語Lymphangiogenesis引起的實體瘤[2]該藥物目前已經進行了I期臨床試驗。[1][2][3]

那吶妥單抗
單株抗體
種類完整抗體
目標RON英語MST1R
臨床資料
ATC碼
  • 未分配
識別資訊
CAS號1188275-92-4  ☒N
ChemSpider
  • none
UNII
KEGG
化學資訊
化學式C6454H10026N1754O2020S44
摩爾質量145,922.10 g·mol−1

那吶妥單抗由ImClone Systems英語ImClone Systems開發。[4]

參考資料

  1. ^ 1.0 1.1 LoRusso, Patricia M.; Gounder, Mrinal; Jalal, Shadia I.; André, Valérie; Kambhampati, Siva Rama Prasad; Loizos, Nick; Hall, Jennifer; Holzer, Timothy R.; Nasir, Aejaz; Cosaert, Jan; Kauh, John. Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors. Investigational New Drugs. 2017-08, 35 (4) [2024-01-24]. ISSN 1573-0646. PMC 5502198 . PMID 28161886. doi:10.1007/s10637-016-0413-0. (原始內容存檔於2024-01-24). 
  2. ^ 2.0 2.1 Saif, Muhammad Wasif; Knost, James A.; Chiorean, E. Gabriela; Kambhampati, Siva Rama Prasad; Yu, Danni; Pytowski, Bronislaw; Qin, Amy; Kauh, John S.; O'Neil, Bert H. Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer. Cancer Chemotherapy and Pharmacology. 2016-10, 78 (4) [2024-01-24]. ISSN 1432-0843. PMID 27566701. doi:10.1007/s00280-016-3134-3. (原始內容存檔於2024-03-22). 
  3. ^ Yu Koh, Xin; Koh, Xin Yu; Xiao Hui Koh; Spiegelberg, Diana; Jha, Preeti; Nestor, Marika; Hwang, Le-ann; Tan, Ban Xiong; Lane, David Philip. Conformation specific antagonistic high affinity antibodies to the RON receptor kinase for imaging and therapy. Scientific Reports. 2022-12-29, 12 (1) [2024-01-24]. ISSN 2045-2322. doi:10.1038/s41598-022-26404-7. (原始內容存檔於2024-01-24) (英語). 
  4. ^ Narnatumumab. AdisInsight. [31 January 2017]. (原始內容存檔於2024-01-24).